natgillin/translations-raw huggingface dataset:
In most reported cases associated with daptomycin, patients developed fever, dyspnoea with hypoxic respiratory insufficiency, and diffuse pulmonary infiltrates or organising pneumonia. 
V večini primerov, o katerih so poročali in ki so bili povezani z daptomicinom, se je pri bolnikih pojavila zvišana telesna temperatura, dispneja s hipoksično respiratorno insuficienco in difuzni pljučni infiltrati ali organizirajoča pljučnica.
Among these failures six patients treated with daptomycin and one patient treated with vancomycin were infected with Staphylococcus aureus that developed increasing MICs of daptomycin on or following therapy (see “Mechanisms of resistance” above). 
Med temi neuspešno zdravljenimi bolniki je bilo šest bolnikov, ki so jih zdravili z daptomicinom, in en bolnik, ki so ga zdravili z vankomicinom, okuženih z bakterijo Staphylococcus aureus, kjer je prišlo do povečevanja MIK daptomicina v času zdravljenja ali po njem (glejte ''Mehanizmi odpornosti'' zgoraj).
Secondary objectives included: Clinical outcome based on the blinded Evaluator's assessment of clinical response (success [cure, improved], failure, or non-evaluable) at the TOC Visit; and Microbiological response (success, failure, or non-evaluable) based on evaluation of Baseline infecting pathogen at TOC. 
Med sekundarnimi cilji sta bila klinični izid po presoji ocenjevalca kliničnega odgovora, s slepim načinom ocenjevanja (uspeh [ozdravitev, izboljšanje], neuspeh ali neocenljivo) pri pregledu za test ozdravitve (TOC) ter mikrobiološki odgovor (uspeh, neuspeh ali neocenljivo) na podlagi ovrednotenja izhodiščnega infekcijskega patogena pri pregledu za test ozdravitve.
Following intravenous administration, plasma clearance of daptomycin is approximately 7 to 9 ml/h/kg and its renal clearance is 4 to 7 ml/h/kg. 
Po intravenskemu dajanju znaša plazemski očistek daptomicina približno 7 do 9 ml/h/kg, ledvični očistek pa 4 do 7 ml/h/kg.
Patients who develop signs or symptoms that might represent a peripheral neuropathy during therapy with daptomycin should be investigated and consideration should be given to discontinuation of daptomycin (see sections 4.8 and 5.3). 
Bolnike, pri katerih se med zdravljenjem z daptomicinom pojavijo znaki ali simptomi, ki bi lahko predstavljali periferno nevropatijo, je treba pregledati in razmisliti o prekinitvi uporabe daptomicina (glejte poglavji 4.8 in 5.3).
Adults - cSSTI without concurrent SAB: daptomycin 4mg/kg is administered once every 24hours for 7-14 days or until the infection is resolved (see section 5.1). 
Odrasli bolniki - cSSTI brez sočasne SAB: daptomicin dajemo v odmerku 4 mg/kg vsakih 24 ur 7-14 dni oziroma dokler okužba ni odpravljena (glejte poglavje 5.1).
Daptomycin Hospira is also used in adults to treat infections in the tissues that line the inside of the heart (including heart valves) which are caused by a type of bacteria called Staphylococcus aureus. 
Pri odraslih se zdravilo Daptomicin Hospira uporablja tudi za zdravljenje okužb tkiv, ki tvorijo notranjo plast srca (vključno s srčnimi zaklopkami), kadar take okužbe povzroča vrsta bakterije z imenom Staphyloccocus aureus.
Daptomycin should only be used in such patients when it is considered that the expected clinical benefit outweighs the potential risk. 
Daptomicin lahko dajemo takim bolnikom le, če pričakovana klinična korist odtehta morebitno tveganje.
The volume of distribution at steady state of daptomycin in healthy adult subjects was approximately 0.1 l/kg and was independent of dose. 
Volumen porazdelitve daptomicina v stanju dinamičnega ravnovesja je pri zdravih odraslih osebah znašal približno 0,1 l/kg in ni bil odvisen od odmerka.
Most patients who failed due to persisting or relapsing Staphylococcus aureus infection had deep-seated infection and did not receive necessary surgical intervention. 
Večina bolnikov, pri katerih zdravljenje ni bilo uspešno zaradi trdovratne ali ponovne okužbe z bakterijo Staphylococcus aureus, je imela globoko okužbo, potrebnega kirurškega posega pa pri njih niso opravili.
There is limited information on the safety and efficacy of daptomycin in the very obese and so caution is recommended. 
Podatki o varnosti in učinkovitosti daptomicina pri zelo debelih bolnikih so omejeni, zato priporočamo previdnost.
During post-marketing surveillance, cases of interference between daptomycin and particular reagents used in some assays of prothrombin time/international normalised ratio (PT/INR) have been reported. 
Med spremljanjem v obdobju trženja zdravila so poročali o primerih interference med daptomicinom in določenimi reagenti, ki jih uporabljamo v nekaterih preskusih za določanje protrombinskega časa/mednarodno umerjenega razmerja (PČ/INR).
In in vitro studies, daptomycin was not metabolised by human liver microsomes. 
V študijah in vitro se daptomicin ni presnavljal preko človeških jetrnih mikrosomov.
Patients were enrolled in a stepwise approach into well-defined age groups and given age-dependent doses once daily for up to 14 days, as follows: 
Bolnike so stopenjsko vključevali v natančno opredeljene starostne skupine in jim zdravilo odmerjali glede na starost največ 14 dni kot sledi:
Any unused portion remaining in the vial should be discarded. 
Neuporabljeno količino zdravila, ki ostane v viali, zavrzite.
In clinical studies, marked increases in plasma CPK to >5x Upper Limit of Normal (ULN) without muscle symptoms occurred more commonly in daptomycin -treated patients (1.9%) than in those that received comparators (0.5%). 
V kliničnih študijah je pri bolnikih, ki so jih zdravili z daptomicinom, prišlo do izrazitega zvišanja ravni CPK v plazmi na > 5kratno zgornjo mejo normale (ZMN) brez mišičnih simptomov bolj pogosto (1,9 %) kot pri tistih bolnikih, ki so prejemali primerjalna zdravila (0,5 %).
Whenever possible, Daptomycin Hospira should be administered following the completion of dialysis on dialysis days (see section 5.2). 
Če je le mogoče, je treba zdravilo Daptomycin Hospira dati na dializne dni po dokončani dializi (glejte poglavje 5.2).
Powder for solution for injection/infusion 1 vial 
prašek za raztopino za injiciranje/infundiranje 1 viala
Your doctor will make sure you have a blood test and will advise whether or not to continue with Daptomycin Hospira. 
Zdravnik bo poskrbel, da boste opravili krvno preiskavo in vam svetoval, ali nadaljevati z uporabo zdravila Daptomicin Hospira ali ne.
In mixed infections where Gram negative and/or certain types of anaerobic bacteria are suspected, daptomycin should be co-administered with appropriate antibacterial agent(s). 
Pri mešanih okužbah, kjer obstaja sum na prisotnost gram negativnih in/ali določenih tipov anaerobnih bakterij, je treba daptomicin dajati skupaj z enim ali več ustreznimi protimikrobnimi zdravili.
Failure of treatment due to persisting or relapsing Staphylococcus aureus infections was observed in 19/120 (15.8%) patients treated with daptomycin, 9/53 (16.7%) patients treated with vancomycin and 2/62 (3.2%) patients treated with an anti-staphylococcal semi-synthetic penicillin. 
Neuspeh zdravljenja zaradi trdovratne ali ponovne okužbe z bakterijo Staphylococcus aureus so opažali pri 19 od 120 bolnikov (15,8 %), ki so jih zdravili z daptomicinom, 9 od 53 bolnikov (16,7 %), ki so jih zdravili z vankomicinom, ter 2 od 62 bolnikov (3,2 %), ki so jih zdravili z antistafilokoknim polsintetičnim penicilinom.
Rare: may affect up to 1 in 1,000 people - Yellowing of the skin and eyes, - Prothrombin time prolonged. 
Redki: pojavijo se lahko pri največ 1 od 1.000 bolnikov - rumeno obarvanje kože in oči - podaljšan protrombinski čas
Following administration of multiple doses, daptomycin exposure was similar across different age groups after dose adjustment based on body weight and age. 
Po uporabi več odmerkov je bila izpostavljenost daptomicinu v različnih starostnih skupinah (po prilagoditvi odmerka glede na telesno maso in starost) podobna.
Secondary objectives included an assessment of efficacy of age-dependent doses of intravenous daptomycin in comparison with standard-of-care therapy. 
Sekundarni cilji so vključevali oceno učinkovitosti posameznih na starost prilagojenih odmerkov intravensko apliciranega daptomicina v primerjavi z uveljavljenim načinom zdravljenja (s standardno oskrbo).
Strains with decreased susceptibility to daptomycin have been reported especially during the treatment of patients with difficult-to-treat infections and/or following administration for prolonged periods. 
Poročali o sevih z zmanjšano občutljivostjo za daptomicin, posebno med zdravljenjem bolnikov z okužbami, ki jih je težko zdraviti, in/ali po dolgotrajnejšem dajanju zdravila.
What Daptomycin Hospira is and what it is used for What you need to know before you are given Daptomycin Hospira How Daptomycin Hospira is given Possible side effects 
Kaj je zdravilo Daptomicin Hospira in za kaj ga uporabljamo Kaj morate vedeti, preden boste uporabili zdravilo Daptomicin Hospira Kako uporabljati zdravilo Daptomicin Hospira Možni neželeni učinki
Clinical studies in patients employed infusion of daptomycin over at least 30 minutes. 
V kliničnih študijah so bolnikom dajali infuzijo daptomicina vsaj 30 minut.
A study in dogs demonstrated that skeletal myopathy was reduced upon once daily administration as compared to fractionated dosing at same total daily dose, suggesting that myopathic effects in animals were primarily related to time between doses. 
V študiji na psih so dokazali zmanjšanje skeletne miopatije pri odmerjanju enkrat dnevno v primerjavi s frakcioniranim odmerjanjem enakega dnevnega odmerka, kar kaže, da so bile miopatske spremembe pri živalih odvisne predvsem od intervalov med odmerjanji.
Daptomycin Hospira given as 30 or 60-minute intravenous infusion 
Zdravilo Daptomicin Hospira za dajanje v obliki 30- ali 60-minutne intravenske infuzije
Daptomycin Hospira is used in adults and in children and adolescents (age from 1 to 17 years) to treat infections of the skin and the tissues below the skin. 
Zdravilo Daptomicin Hospira uporabljamo pri odraslih in otrocih ter mladostnikih (starih od 1 do 17 let) za zdravljenje okužb kože in podkožnih tkiv.
The Marketing Authorisation Holder shall ensure that all physicians who are expected to prescribe/use Daptomycin Hospira are provided with: - Summary of Product Characteristics - Dosage card 
Imetnik dovoljenja za promet z zdravilom mora zagotoviti, da bodo vsi zdravniki, ki bodo predvidoma predpisovali/uporabljali zdravilo Daptomicin Hospira, prejeli: - povzetek glavnih značilnosti zdravila, - kartico za odmerjanje daptomicina.
The primary objective of Study DAP-PEDBAC-11-02 was to assess the safety of intravenous daptomycin versus SOC antibiotics. 
Primarni cilj študije DAP-PEDBAC-11-02 je bil oceniti varnost intravenskega daptomicina v primerjavi z antibiotiki, ki se uporabljajo za standardno oskrbo.
The reconstituted solution should be checked carefullyto ensure that the product is in solution and visually inspected for the absence of particulates prior to use. 
Rekonstituirano raztopino morate pazljivo preveriti in se prepričati, da je zdravilo v raztopini, ter jo pred uporabo vizualno pregledati, da v njej ni trdnih delcev.
The most serious side effects are described below: 
Spodaj so navedeni najbolj resni neželeni učinki:
UNIQUE IDENTIFIER -2D BARCODE 
EDINSTVENA OZNAKA - DVODIMENZIONALNA ČRTNA KODA
Daptomycin Hospira is available in packs containing 1 vial or 5 vials. 
Zdravilo Daptomicin Hospira je na voljo v pakiranjih po 1 ali 5 vial.
As necessary, expert advice should be sought when the local prevalence of resistance is such that the utility of the agent in at least some types of infections is questionable. 
Kadar je lokalna razširjenost odpornosti takšna, da je koristnost zdravila pri vsaj nekaterih vrstah okužb vprašljiva, je treba po potrebi pridobiti mnenje strokovnjaka.
The safety and efficacy of daptomycin in children and adolescents aged below 18 years with RIE due to Staphylococcus aureus have not been established. 
Varnost in učinkovitost daptomicina pri otrocih in mladostnikih do 18. leta starosti z RIE zaradi bakterije Staphylococcus aureus nista bili dokazani.
If you are allergic to daptomycin or to sodium hydroxide or to any of the other ingredients of this medicine (listed in section 6). 
Ne uporabljajte zdravila Daptomicin Hospira: če ste alergični na daptomicin, natrijev hidroksid ali katerokoli sestavino tega zdravila (navedeno v poglavju 6).
1 to 6 years (N=19)* 
1 do 6 let (N = 19)*
Paediatric patients below the age of one year should not be given daptomycin due to the risk of potential effects on muscular, neuromuscular and/or nervous systems (either peripheral and/or central) that were observed in neonatal dogs (see section 5.3). 
Pediatrični bolniki, ki so stari manj kot eno leto, daptomicina ne smejo prejemati zaradi tveganja za morebitne učinke na mišični, živčno-mišični in/ali živčni sistem (periferni in/ali centralni), kar so opažali pri novoskotenih pasjih mladičih (glejte poglavje 5.3).
About 5% of the administered radiolabel was excreted in the faeces. 
Približno 5 % danega radioaktivno označenega zdravila se je izločilo z blatom.
Driving and using machines Daptomycin Hospira has no known effects on the ability to drive or use machines. 
Vpliv na sposobnost upravljanja vozil in strojev Daptomicin nima znanega vpliva na sposobnost vožnje in upravljanja strojev.
In particular, there have been reports of treatment failures in patients infected with Staphylococcus aureus, Enterococcus faecalis or Enterococcus faecium, including bacteraemic patients, that have been associated with the selection of organisms with reduced susceptibility or frank resistance to daptomycin during therapy. 
O neuspehu zdravljenja so poročali predvsem pri bolnikih, ki so bili okuženi z bakterijo Staphylococcus aureus, Enterococcus faecalis ali Enterococcus faecium, med drugim tudi pri bolnikih z bakteriemijo, neuspeh pa je bil povezan z organizmi, ki so med zdravljenjem postali manj občutljivi za daptomicin ali očitno odporni proti njemu.
Daptomycin pharmacokinetics in patients in this study are summarised in Table 2. 
Farmakokinetika daptomicina pri bolnikih v tej študiji je povzeta v preglednici 2.
Daptomycin Hospira is not physically or chemically compatible with glucose-containing solutions. 
Zdravilo Daptomicin Hospira fizikalno ali kemijsko ni združljivo z raztopinami, ki vsebujejo glukozo.
The key efficacy endpoint was the sponsor-defined clinical outcome at test-of-cure (TOC), which was defined by a blinded medical director. 
Ključni cilj opazovanja za oceno učinkovitosti je bil klinični izid po definiciji naročnika glede na test ozdravitve (TOC-test-of-cure), ki ga je opredelil direktor medicinskega oddelka s slepim načinom ocenjevanja.
On the basis of reported adverse drug reactions, daptomycin is presumed to be unlikely to produce an effect on the ability to drive or use machinery. 
Glede na neželene učinke, o katerih so poročali, je malo verjetno, da bi daptomicin vplival na sposobnost vožnje in upravljanja strojev.
No dose adjustment is necessary based on age alone. 
Zgolj na osnovi starosti prilagajanje odmerka ni potrebno.
Dose Infusion Time 
Odmerek Čas infundiranja
Single use 10 ml type I clear glass vials with gray rubber closure and aluminium cap. 
10 ml viale za enkratno uporabo iz prozornega stekla tipa I s sivim gumijastim zamaškom in aluminijasto zaporko.
PP (per protocol) Population RIE 
PP-populacija (populacija, ki so jo zdravili skladno s protokolom) RIE
2 (increased alanine aminotransferase (ALT), aspartate aminotransferase (AST) or alkaline phosphatase (ALP)) 
nenormalni izvidi preiskav delovanja jeter 2 (zvišane vrednosti alaninaminotransferaze (ALT), aspart-ataminotransferaze (AST) ali alkalne fosfataze (ALP))
Eosinophilic pneumonia 
Eozinofilna pljučnica
If a focus of infection other than cSSTI or RIE is identified after initiation of daptomycin therapy consideration should be given to instituting alternative antibacterial therapy that has been demonstrated to be efficacious in the treatment of the specific type of infection(s) present. 
Če po začetku zdravljenja z daptomicinom ugotovimo, da žarišče okužbe ni cSSTI oziroma RIE, je treba razmisliti o uvedbi zdravljenja z drugim antibiotikom, ki je dokazano učinkovit pri zdravljenju specifične okužbe (okužb), ki je prisotna.
60 minutes cSSTI = complicated skin and soft-tissue infections; SAB = S. aureus bacteraemia; (1) Minimum duration of Daptomycin Hospira for paediatric SAB should be in accordance with the perceived risk of complications in the individual patient. 
24 ur v infuziji, ki traja 60 minut cSSTI = zapletene okužbe kože in mehkih tkiv, SAB = bakteriemija z bakterijo S. aureus (1) Minimalno trajanje zdravljenja z daptomicinom pri pediatričnih bolnikih mora biti v skladu z ocenjenim tveganjem za zaplete pri posameznem bolniku.
Your doctor will check the condition of your lungs and decide whether or not you should continue Daptomycin Hospira treatment. 
Zdravnik bo preveril stanje vaših pljuč in se odločil, ali lahko nadaljujete zdravljenje z zdravilom Daptomicin Hospira ali ne.
If this applies to you, tell your doctor or nurse. 
Če to velja za vas, obvestite svojega zdravnika ali medicinsko sestro.
Expelair, large bubbles, and any excess solution in order to obtain the required dose. 
Iztisnite zrak, velike mehurčke in morebitno odvečno količino raztopine, da dobite zahtevani odmerek.
Simulation using a population pharmacokinetic model demonstrated that the AUCss (area under the concentration-time curve at steady state) of daptomycin in paediatric patients 1 to <2 years of age receiving12 mg/kg once daily would be comparable to that in adult patients receiving 6 mg/kg once daily. 
Simulacija z uporabo populacijskega farmakokinetičnega modela je pokazala, da je AUCss (površina pod krivuljo koncentracije v odvisnosti od časa v stanju dinamičnega ravnovesja) za daptomicin pri pediatričnih bolnikih, starih od 1 do < 2 let, ki so prejemali 12 mg/kg enkrat dnevno, primerljiva s tistim pri odraslih bolnikih, ki so prejemali 6 mg/kg enkrat dnevno.
Daptomycin had no effect on the pharmacokinetics of warfarin or probenecid, nor did these medicinal products alter the pharmacokinetics of daptomycin. 
Daptomicin ni vplival na farmakokinetične lastnosti varfarina in probenecida, navedeni zdravili pa nista vplivali na farmakokinetične lastnosti daptomicina.
The lowest observable effect level (LOEL) for myopathy in rats and dogs occurred at exposure levels of 0.8 to 2.3-fold the human therapeutic levels at 6 mg/kg (30-minute intravenous infusion) for patients with normal renal function. 
Najnižjo koncentracijo z opaznim učinkom (LOEL - Lowest Observable Effect Level) za miopatijo so pri podganah in psih opazili pri stopnjah izpostavljenosti, ki so bile 0,8 do 2,3-kratniki terapevtskih koncentracij pri človeku pri odmerku 6 mg/kg (30-minutna intravenska infuzija) pri bolnikih z normalnim delovanjem ledvic.
The microbiological outcome at TOC for the daptomycin and SOC treatment arms for infections caused by MRSA and MSSA are presented in the table below (mMITT population). 
Mikrobiološki izidi pri testu ozdravitve za skupini z daptomicinom in standardno oskrbo pri okužbah z MRSA in MSSA so prikazani v spodnji preglednici (populacija mMITT).
Caution is advised when administering daptomycin to patients who already have some degree of renal impairment (creatinine clearance <80 ml/min) before commencing therapy with Daptomycin Hospira. 
Pri dajanju daptomicina bolnikom, ki že imajo določeno stopnjo okvare ledvic (očistek kreatinina < 80 ml/min) pred začetkom zdravljenja z zdravilom Daptomicin Hospira, je potrebna previdnost.
Therefore, until more experience is gained, breast-feeding should be discontinued when daptomycin is administered to nursing women. 
Dokler ne bo na voljo več izkušenj zato velja, da je treba prenehati z dojenjem, če doječa mati prejema daptomicin.
Daptomycin Hospira vials are for single-use only. 
Viale z zdravilom Daptomicin Hospira so samo za enkratno uporabo.
If not used immediately, in-use storage times are the responsibility of the user and would not normally be longer than 24 hours at 2°C-8°C, unless reconstitution/dilution has taken place in controlled and validated aseptic conditions. 
Če zdravila ne uporabite takoj, je za čas shranjevanja med uporabo, ki normalno ne sme presegati 24 ur pri temperaturi 2 °C - 8 °C, odgovoren uporabnik, razen če je rekonstitucija/redčenje zdravila potekala v nadzorovanih in validiranih aseptičnih pogojih.
What Daptomycin Hospira is and what it is used for 
Kaj je zdravilo Daptomicin Hospira in za kaj ga uporabljamo
There is insufficient evidence to be able to draw any conclusions regarding the possible clinical efficacy of daptomycin against infections due to enterococci, including Enterococcus faecalis and Enterococcus faecium. 
Za sklepanje o morebitni klinični učinkovitosti daptomicina pri zdravljenju okužb z enterokoki, vključno z bakterijama Enterococcus faecalis in Enterococcus faecium, ni dovolj dokazov.
These could interfere with the effects of Daptomycin Hospira in the kidney. 
Ta zdravila lahko vplivajo na učinke zdravila Daptomicin Hospira v ledvicah.
Anxiety, insomnia 
tesnoba, nespečnost
It is recommended that other medicinal products associated with myopathy should if possible be temporarily discontinued during treatment with daptomycin unless the benefits of concomitant administration outweigh the risk. 
Priporočamo, da med zdravljenjem z daptomicinom po možnosti začasno prekinete zdravljenje z drugimi zdravili, povezanimi z nastankom miopatij, razen v primeru, da koristi sočasne uporabe odtehtajo tveganja.
Concomitant administration of probenecid and daptomycin has no effect on daptomycin pharmacokinetics in humans suggesting minimal to no active tubular secretion of daptomycin. 
Sočasno dajanje probenecida in daptomicina nima vpliva na farmakokinetiko daptomicina pri ljudeh, kar kaže na minimalno ali neobstoječo aktivno tubularno sekrecijo daptomicina.
Creatine phosphokinase and myopathy Increases in plasma creatine phosphokinase (CPK; MM isoenzyme) levels associated with muscular pains and/or weakness and cases of myositis, myoglobinaemia and rhabdomyolysis have been reported during therapy with daptomycin (see also sections 4.5, 4.8 and 5.3). 
Kreatin-fosfokinaza in miopatija Med zdravljenjem z daptomicinom so poročali o zvišanju ravni kreatin-fosfokinaze v plazmi (CPK, izoencim MM), povezanem z bolečinami v mišicah in/ali mišično oslabelostjo, in primerih miozitisa, mioglobinemije in rabdomiolize (glejte tudi poglavja 4.5, 4.8 in 5.3).
What Daptomycin Hospira looks like and contents of the pack Daptomycin Hospira powder for solution for injection/infusion is supplied as a light yellow to light brown lyophilised cake or powder in a glass vial. 
Izgled zdravila Daptomicin Hospira in vsebina pakiranja Zdravilo Daptomicin Hospira prašek za raztopino za injiciranje/infundiranje je na voljo kot svetlo rumena do svetlo rjava liofilizirana pogača ali prašek v stekleni viali.
Comments cSSTI without SAB 
Opombe cSSTI brez SAB
To minimise this risk, physicians should be advised that for coagulation levels testing it is recommended to draw blood samples near the time of Daptomycin Hospira trough plasma concentration. 
Za zmanjšanje tveganja za napačne rezultate je treba zdravnikom svetovati, naj vzorce krvi jemljejo približno v času, ko je koncentracija zdravila Daptomicin Hospira v plazmi najnižja.
Experience with the concomitant administration of daptomycin and warfarin is limited. 
Izkušenj s sočasno uporabo daptomicina in varfarina je malo.
- Adult patients with right-sided infective endocarditis (RIE) due to Staphylococcus aureus. 
- pri odraslih bolnikih z desnostranskim infekcijskim endokarditisom (RIE - Right-sided Infective Endocarditis) zaradi bakterije Staphylococcus aureus.
- Occasionally, patients receiving Daptomycin Hospira may develop tender or aching muscles or muscle weakness (see section 4 of this leaflet for more information). 
- občasno se lahko pri bolnikih, ki prejemajo daptomicin, pojavijo občutljivost ali bolečine v mišicah ali mišična oslabelost (za več informacij glejte poglavje 4 v tem navodilu za uporabo).